Day: July 30, 2023

Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy

Staff July 30, 2023

No indication that drug product or manufacturing issues contributed to rare events of retinal vasculitisConfirmed seven total events of non-occlusive/occlusive...

Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS

Staff July 30, 2023

89% and 84% of patients were maintained on ≥12- and ≥16-week dosing intervals, respectively, throughout the two-year period, while sustaining their...

4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023

Staff July 30, 2023

4D-150 clinical efficacy endpoints for evaluable patients in all three cohorts (n=14) at 36 weeks Table for 4D-150 clinical efficacy...

Day: July 30, 2023

Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy

Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS

4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023

Redefining the Standard of Care: Introducing the Aulisa® Monitor Camera for Advanced Patient Monitoring

Fitness App Market to Expand by USD 55.86 Billion (2024-2028), Driven by Health Management and Rising Chronic Disease Cases, AI Impacting Market Trends – Technavio

Defence Announces Closing of Securities for Debenture Financing

NuGen Announces Canada-Wide Launch of InsuJet

purelyIV Launches Mobile App for Seamless Wellness Management

You may have missed